GPR30 is a potential player between islet cells and ductal HCO 3 - secretion.

Autor: Venglovecz V; Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary; Translational Pancreatology Research Group, Interdisciplinary Center of Excellence for Research Development and Innovation, University of Szeged, Szeged, Hungary; Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary., Hegyi P; Translational Pancreatology Research Group, Interdisciplinary Center of Excellence for Research Development and Innovation, University of Szeged, Szeged, Hungary; Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary; Centre for Translational Medicine, Semmelweis University, Budapest, Hungary; Institute for Pancreatic Disorders, Semmelweis University, Budapest, Hungary. Electronic address: hegyi.peter@semmelweis.hu.
Jazyk: angličtina
Zdroj: Cell calcium [Cell Calcium] 2024 Nov; Vol. 123, pp. 102922. Date of Electronic Publication: 2024 Jun 13.
DOI: 10.1016/j.ceca.2024.102922
Abstrakt: The primary role of pancreatic ductal HCO 3 - secretion is to prevent premature activation of digestive enzymes and to provide a vehicle for the delivery of enzymes to the duodenum. In addition, HCO 3 - is responsible for the neutralization of gastric juice and protect against the formation of protein plugs and viscous mucus. Due to this multifaceted role of HCO 3 - in the pancreas, its altered functioning can greatly contribute to the development of various exocrine diseases. It is well known that the exocrine and endocrine pancreas interact lively with each other, but not all details of this relationship are known. An interesting finding of a recent study by Jo-Watanabe et al. is that the G protein-coupled oestrogen receptor, GPR30, which is expressed in the endocrine pancreas, can be also activated by HCO 3 - . This raises the possibility that ductal cells play a key role not only in the exocrine pancreas, but presumably also in endocrine function through HCO 3 - secretion.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Peter Hegyi reports financial support was provided by CF-Trust. Viktoria Venglovecz reports financial support was provided by National Research Development and Innovation Office. Peter Hegyi reports a relationship with National Research Development and Innovation Office that includes: funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: